<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01008345</url>
  </required_header>
  <id_info>
    <org_study_id>pharmaline1</org_study_id>
    <nct_id>NCT01008345</nct_id>
  </id_info>
  <brief_title>Effect of Ezetimibe on Oxidized Low-density Lipoprotein (LDL) Cholesterol</brief_title>
  <official_title>Effect of Ezetimibe on Oxidized LDL Cholesterol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hotel Dieu de France Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pharmaline, Lebanon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hotel Dieu de France Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized study. Patients with coronary artery disease equivalent will be randomized to
      receive atorvastatin 40 mg/day + placebo vs. atorvastatin 40 mg/day + ezetimibe 40 mg/day.
      Oxidized LDL cholesterol will be measured at baseline and after 8 weeks of treatment.
      Hypothesis is that ezetimibe will lower oxidized LDL
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>level of oxidized LDL cholesterol at end of study</measure>
    <time_frame>8 weeks of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>small dense LDL level</measure>
    <time_frame>8 weeks of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>ezetimibe</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>will receive the active treatment with ezetimibe and statin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ezetimibe</intervention_name>
    <description>Patients will receive 10 mg/day of ezetimibe for 8 weeks</description>
    <arm_group_label>ezetimibe</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  CAD or CAD equivalent

        Exclusion Criteria:

          -  Prior CABG or PCI within 3 months Prior use of ezetimibe within 3 months Receiving
             atorvastatin 40 mg/day or 80 mg/day or any dose of rosuvastatin CHF NYHA stage &gt;2
             Creatinin clearance &lt; 30 ml/min
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>rabih azar, md</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hotel Dieu</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hotel Dieu de France Hospital</name>
      <address>
        <city>Achrafieh</city>
        <state>Beirut</state>
        <zip>0000</zip>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Lebanon</country>
  </location_countries>
  <verification_date>November 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 4, 2009</study_first_submitted>
  <study_first_submitted_qc>November 4, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 5, 2009</study_first_posted>
  <last_update_submitted>November 5, 2009</last_update_submitted>
  <last_update_submitted_qc>November 5, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 6, 2009</last_update_posted>
  <responsible_party>
    <name_title>Rabih Azar, MD</name_title>
    <organization>Hotel Dieu de France Hospital</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ezetimibe</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

